Endothelial Progenitor Cells for Ischemic Stroke: Update on Basic Research and Application

Liao, Shaohua; Luo, Chunxia; Cao, Bingzhen; Hu, Huaiqiang; Wang, Suxia; Yue, Huili; Chen, Lin; Zhou, Zhenhua

doi:10.1155/2017/2193432

Cited by 46 publications

(43 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the setting of DVT, endothelial progenitor cells (EPCs), which are a type of bone marrow‐derived circulating progenitor cell in the endothelial lineage, have been reported to have the abilities to home in on and migrate to disease sites to facilitate thrombus recanalization and resolution by neovascularization, increase new blood vessel formation at the injured site, and secrete a variety of vasoactive and angiogenic factors to improve angiogenesis . Furthermore, EPCs have the capacity to protect differentiated endothelial cells from apoptosis, thereby preserving their angiogenic potential under conditions of oxidative stress .…”

Section: Introductionmentioning

confidence: 99%

LncRNA WTAPP1 Promotes Migration and Angiogenesis of Endothelial Progenitor Cells via MMP1 Through MicroRNA 3120 and Akt/PI3K/Autophagy Pathways

Zhou

Sun

et al. 2018

Stem Cells

View full text Add to dashboard Cite

Efficient recruitment and angiogenesis of endothelial progenitor cells (EPCs) are critical during a thrombus event. However, the details of EPC recruitment and the regulation of angiogenesis have not been fully determined. The aim of this study was to determine the role of the long noncoding (lnc)RNA Wilms tumor 1 associated protein pseudogene 1 (WTAPP1) in regulation of the migration and angiogenesis of EPCs. EPCs were isolated from human peripheral blood and characterized by flow cytometry, after which lentivirus-mediated lncRNA WTAPP1 overexpression and knockdown were performed. Scratch assay, Transwell assay, and in vitro and in vivo tube formation assays were performed to measure cell migration, invasion, and angiogenic abilities, respectively. Moreover, a microarray screen, bioinformatic prediction, and quantitative PCR and western blot of miRNAs interacting with lncRNA WTAPP1 were conducted. Western blot was carried out to elucidate the relationship among WTAPP1, miR-3120-5P, and MMP-1 in the autophagy pathway. WTAPP1 positively regulated migration, invasion, and in vitro and in vivo tube formation in EPCs by increasing MMP-1 expression and activating PI3K/Akt/mTOR signaling. Furthermore, WTAPP1 contains a putative miR-3120-5P binding site. Suppression of WTAPP1 by miR-3120-5P decreased the level of MMP-1. In addition, we demonstrated that suppression of the autophagy pathway is involved in the effects of WTAPP1 on EPC migration and angiogenesis. The lncRNA WTAPP1, a molecular decoy for miR-3120-5p, regulates MMP-1 expression via the PI3K/Akt and autophagy pathways, thereby mediating cell migration and angiogenesis in EPCs. Acting as a potential therapeutic target, the lncRNA WTAPP1 may play an important role in the pathogenesis of DVT. Stem Cells 2018.

show abstract

Section: Introductionmentioning

confidence: 99%

LncRNA WTAPP1 Promotes Migration and Angiogenesis of Endothelial Progenitor Cells via MMP1 Through MicroRNA 3120 and Akt/PI3K/Autophagy Pathways

Zhou

Sun

et al. 2018

Stem Cells

View full text Add to dashboard Cite

show abstract

“…EPCs have been also shown to decrease neuronal apoptosis and promote the proliferation and migration of neural stem cells by repairing vascular endothelial cells and inducing neo-vascularization in animal models of cerebral ischemia. Growth factor (e.g., VEGF) secretion by EPCs contributes to post-stroke angiogenesis and neurogenesis, thereby reconstructing the functions and structures of vascular and neural networks ( 22 , 89 , 90 ).…”

Section: Therapeutic Implications Of Naïve Stem Cellsmentioning

confidence: 99%

“…EPCs also contribute to neovascularization and tissue repair of musculoskeletal and neural tissue including the bone and spinal cord. Transplantation of EPCs has been used to treat ischemic diseases in animal models and clinical trials ( 20 – 22 ).…”

Section: Introductionmentioning

confidence: 99%

Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review)

et al. 2018

View full text Add to dashboard Cite

The tissue kallikrein-kinin system (KKS) is an endogenous multiprotein metabolic cascade which is implicated in the homeostasis of the cardiovascular, renal and central nervous system. Human tissue kallikrein (KLK1) is a serine protease, component of the KKS that has been demonstrated to exert pleiotropic beneficial effects in protection from tissue injury through its anti-inflammatory, anti-apoptotic, anti-fibrotic and anti-oxidative actions. Mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) constitute populations of well-characterized, readily obtainable multipotent cells with special immunomodulatory, migratory and paracrine properties rendering them appealing potential therapeutics in experimental animal models of various diseases. Genetic modification enhances their inherent properties. MSCs or EPCs are competent cellular vehicles for drug and/or gene delivery in the targeted treatment of diseases. KLK1 gene delivery using adenoviral vectors or KLK1 protein infusion into injured tissues of animal models has provided particularly encouraging results in attenuating or reversing myocardial, renal and cerebrovascular ischemic phenotype and tissue damage, thus paving the way for the administration of genetically modified MSCs or EPCs with the human tissue KLK1 gene. Engraftment of KLK1-modified MSCs and/or KLK1-modified EPCs resulted in advanced beneficial outcome regarding heart and kidney protection and recovery from ischemic insults. Collectively, findings from pre-clinical studies raise the possibility that tissue KLK1 may be a novel future therapeutic target in the treatment of a wide range of cardiovascular, cerebrovascular and renal disorders.

show abstract

“…Stem cell therapy, using hematopoietic stem cells (HSCs), 8 , 9 neural stem cells (NSCs), 10 , 11 endothelial progenitor cells (EPCs) 12 and other types of stem cells, 13 , 14 was considered a promising treatment for IS as it may reduce injury and promote rehabilitation after stroke. Mesenchymal stem cells (MSCs) are derived from mesoderm and have the capacity of regeneration and differentiation.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell transplantation as an effective treatment strategy for ischemic stroke in Asia: a meta-analysis of controlled trials

Xue

Wang

Yan

2018

TCRM

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to evaluate the efficacy and safety of the mesenchymal stem cell (MSC) therapy in patients with ischemic stroke (IS).Materials and methodsClinical trials involved in this research were searched from PubMed, Web of Science, Cochrane Library, Embase, Wanfang and CNKI database. Therapeutic effects of MSC therapy were assessed according to National Institutes of Health Stroke Scale (NIHSS), Barthel index (BI), Fugl-Meyer Assessment (FMA) and Functional Independence Measure (FIM), and its safety was evaluated based on adverse events.ResultsThis research covered 23 trials including 1,279 IS patients. Based on our analysis, the overall condition of IS patients significantly improved after MSC therapy, indicated by decreased NIHSS and increased BI, FMA and FIM scores. Our analysis also showed that the treatment effects in the MSC transplantation group were superior to those in the control group (routine medication therapy) with statistical significance for NIHSS (1 month after therapy: odds ratio [OR]=−1.92, CI=−3.49 to −0.34, P=0.02; 3 months after therapy: OR=−2.65, CI=−3.40 to −1.90, P<0.00001), BI (1 month after therapy: OR=0.99, CI=0.19–1.79, P=0.02; 6 months after therapy: OR=10.10, CI=3.07–17.14, P=0.005), FMA (3 months after therapy: OR=10.20, CI=3.70–16.70, P=0.002; 6 months after therapy: OR=10.82, CI=6.45–15.18, P<0.00001) and FIM (1 month after therapy: OR=15.61, CI=−0.02 to 31.24, P=0.05; 6 months after therapy: OR=16.56, CI=9.06–24.06, P<0.0001). No serious adverse events were reported during MSC therapy.ConclusionMSC therapy is safe and effective in treating IS by improving the neurological deficits, motor function and daily life quality of patients.

show abstract

Endothelial Progenitor Cells for Ischemic Stroke: Update on Basic Research and Application

Cited by 46 publications

References 156 publications

LncRNA WTAPP1 Promotes Migration and Angiogenesis of Endothelial Progenitor Cells via MMP1 Through MicroRNA 3120 and Akt/PI3K/Autophagy Pathways

LncRNA WTAPP1 Promotes Migration and Angiogenesis of Endothelial Progenitor Cells via MMP1 Through MicroRNA 3120 and Akt/PI3K/Autophagy Pathways

Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review)

Mesenchymal stem cell transplantation as an effective treatment strategy for ischemic stroke in Asia: a meta-analysis of controlled trials

Contact Info

Product

Resources

About